The optimal CD4/CD8 ratio of chimeric antigen receptor (CAR) T cells is approximately 1:1, which confers a favorable advantage for eliciting an effective anti-tumor response within the host organism [38, 39]. The gene discussed is CD8A; the disease is neoplasm.